Carbapenem-Resistant Acinetobacter baumannii: Applying Best Practices in Complex Clinical Scenarios

In this episode, Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections involving carbapenem-resistant Acinetobacter baumannii (CRAB), including: 

• Mechanisms for β-lactam resistance
• Additional resistance mechanisms and virulence factors
• 2023 IDSA guidance recommendations for moderate to severe CRAB infections
• The latest clinical data by antimicrobial therapy/regimen:
• Sulbactam
• Meropenem and colistin
• Carbapenem, sulbactam, and polymyxin B
• Tetracyclines
• Cefiderocol
• Sulbactam/durlobactam and carbapenems
   

Program Director:

Trevor Van Schooneveld, MD, FSHEA, FACP 
Professor, Division of Infectious Diseases
Program Director, Infectious Diseases Fellowship
Medical Director, Antimicrobial Stewardship Program
University of Nebraska Medical Center
Omaha, Nebraska

Faculty:

Emily Heil, PharmD, MS, BCIDP, AAHIVP
Associate Professor
Department of Pharmacy
University of Maryland 
School of Pharmacy
ID Clinical Pharmacy Specialist
University of Maryland Medical Center
Baltimore, Maryland

Laila Woc-Colburn, MD
Associate Professor
Division of Infectious Diseases
Emory University School of Medicine 
Atlanta, Georgia

Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Follow along with a downloadable slideset at: 
https://bit.ly/476v2wI

Link to full program: 
https://bit.ly/40Mmicz

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.